Why Vertex Pharmaceuticals' Shares Rose 2.8% in September

Why Vertex Pharmaceuticals' Shares Rose 2.8% in September

Submitted by admin on October 5, 2022 - 10:33am
Source: 
Motley Fool
News Tags: 
Vertex Pharmaceuticals
Trikafta
R&D
cystic fibrosis
Headline: 
Why Vertex Pharmaceuticals' Shares Rose 2.8% in September
snippet: 
  • Vertex, known for its cystic fibrosis therapies, is branching out into gene-editing therapies for rare genetic blood disorders.
  • The company’s revenue was up in the second quarter by 12% year over year.
  • Vertex’s cystic fibrosis drug, Trikafta, is helping the company bankroll research and development.

Do Not Allow Advertisers to Use My Personal information